loading page

Interim PET-CT: Predictive marker and therapeutic modification tool of pediatric Hodgkin lymphoma
  • +5
  • Pankaj Dwivedi,
  • Manish Mathankar,
  • Chaitali Bongulwar,
  • Ketan Modak,
  • Madhabika Chakraborty,
  • Atul Kapse,
  • Meena Pangarkar,
  • Nitin Manvani
Pankaj Dwivedi
National Cancer Institute

Corresponding Author:[email protected]

Author Profile
Manish Mathankar
National Cancer Institute Nagpur
Author Profile
Chaitali Bongulwar
National Cancer Institute Nagpur
Author Profile
Ketan Modak
National Cancer Institute Nagpur
Author Profile
Madhabika Chakraborty
National Cancer Institute Nagpur
Author Profile
Atul Kapse
National Cancer Institute
Author Profile
Meena Pangarkar
National Cancer Institute Nagpur
Author Profile
Nitin Manvani
National Cancer Institute
Author Profile

Abstract

Hodgkin lymphoma is a haematolymphoid malignancy seen in pediatric and adult age groups with an excellent outcome. The current priority of the treatment has been a reduction of acute and chronic morbidities without compromising outcomes. PET-CT scan is an integral component in prognosticating and determining outcomes in Hodgkin lymphoma. Recent studies have highlighted the role of interim PET-CT scan in choosing future therapy. The evidence to support the role of interim PET-CT scan in childhood Hodgkin lymphoma is limited. The aim of the study is to analyse the role of interim PET-CT in the management of childhood HL, and to investigate survival outcomes of children treated at our institute. This is a retrospective study and included all the children with HL treated at our institute in last five years. All the children were treated as per ESMO guidelines. Interim PET-CT scan was done after two cycles of chemotherapy. The correlation of various possible risk factors with the outcomes was examined. Only the interim PET/CT findings were associated with the results. At median follow-up of 34 months, the event free survival (EFS) was 95.7% and overall survival (OS) was 100%. Interim PET-CT plays an important role in treatment modification without compromising on the outcomes in children with HL. Survival rates were consistent with those reported in published literature.
03 Jun 2023Submitted to Cancer Reports
06 Jun 2023Submission Checks Completed
06 Jun 2023Assigned to Editor
06 Jun 2023Review(s) Completed, Editorial Evaluation Pending
07 Jun 2023Reviewer(s) Assigned
17 Jul 2023Editorial Decision: Revise Major